(4S,4AS,5AR,12AS)-4-(二甲基氨基)-1,4,4A,5,5A,6,11,12A-八氢-3,10,12,12A-四羟基-7-[(甲氧基甲基氨基)甲基]-1,11-二氧代-2-并四苯甲酰胺盐酸盐
中文名称 | (4S,4AS,5AR,12AS)-4-(二甲基氨基)-1,4,4A,5,5A,6,11,12A-八氢-3,10,12,12A-四羟基-7-[(甲氧基甲基氨基)甲基]-1,11-二氧代-2-并四苯甲酰胺盐酸盐 |
---|---|
中文同义词 | (4S,4AS,5AR,12AS)-4-(二甲基氨基)-1,4,4A,5,5A,6,11,12A-八氢-3,10,12,12A-四羟基-7-[(甲氧基甲基氨基)甲基]-1,11-二氧代-2-并四苯甲酰胺盐酸盐;麦芽糖醇杂质14;米诺环素杂质14;沙雷霉素;盐酸沙林霉素;(4S,4AS,5AR,12AS)-4-(二甲基氨基)-1,4,4A,5,5A,6,11,12A-八氢-3,10,12,12A-四羟基-7-[(甲氧基甲基氨基)甲基]-1,11-二氧代-2-并四苯甲酰;13C,2H3]-沙利环素盐酸盐;沙环素盐酸盐 |
英文名称 | Sarecycline Hydrochloride |
英文同义词 | (4S,4aS,5aR,12aS)-4-(DiMethylaMino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-7-[(MethoxyMethylaMino)Methyl]-1,11-dioxo-2-naphthacenecarboxaMide hydrochloride;Sarecycline (hydrochloride);4S,4aS,5aR,12aS)-4-(Dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-7-[(methoxymethylamino)methyl]-1,11-dioxo-2-naphthacenecarboxamide hydrochloride P005672 HCl;(4S,4AS,5aR,12aS)-4-(dimethylamino)-3,10,12,12a-tetrahydroxy-7-((methoxy(methyl)amino)methyl)-;P005672 HCl (Sarecycline HCl);PO05672 HCl;Minocycline Impurity 14;CS-267 |
CAS号 | 1035979-44-2 |
分子式 | C24H30ClN3O8 |
分子量 | 523.97 |
EINECS号 | |
相关类别 | 信号转导通路激酶抑制剂;抑制剂 |
Mol文件 | 1035979-44-2.mol |
结构式 |
(4S,4AS,5AR,12AS)-4-(二甲基氨基)-1,4,4A,5,5A,6,11,12A-八氢-3,10,12,12A-四羟基-7-[(甲氧基甲基氨基)甲基]-1,11-二氧代-2-并四苯甲酰胺盐酸盐 性质
储存条件 | Store at -20°C |
---|---|
溶解度 | DMF:0.25mg/mL,DMSO:0.25mg/mL |
(4S,4AS,5AR,12AS)-4-(二甲基氨基)-1,4,4A,5,5A,6,11,12A-八氢-3,10,12,12A-四羟基-7-[(甲氧基甲基氨基)甲基]-1,11-二氧代-2-并四苯甲酰胺盐酸盐 用途与合成方法
Sarecycline inhibits 55 clinical isolates of
C. acnes
, and the MIC values for Sarecycline ranged from 0.5 to 16 µg/ml; the MIC
50
was 0.5 µg/ml, and the MIC
90
was 4 µg/ml. Sarecycline, exhibits activity against the macrolide-resistant organisms.
Sarecycline hydrochloride exhibits minimal activity against enteric aerobic Gram-negative bacteria.
Sarecycline hydrochloride (0.33-9 mg/kg; i.v.) show potent activity against S. aureus in a murine neutropenic thigh infection model.
Animal Model: | Female SD-1 mice (A murine neutropenic thigh wound infection model) |
Dosage: | 0.33, 1, 3, or 9 mg/kg |
Administration: | Intravenously |
Result: | Achieved a 2-log10 reduction in the bacterial burden in the thigh at a dose comparable to that of doxycycline, with ED50s of 8.23 and 8.32 mg/kg, respectively. |
安全信息
更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
---|---|---|---|---|---|
2024/01/25 | HY-13858A | (4S,4AS,5AR,12AS)-4-(二甲基氨基)-1,4,4A,5,5A,6,11,12A-八氢-3,10,12,12A-四羟基-7-[(甲氧基甲基氨基)甲基]-1,11-二氧代-2-并四苯甲酰胺盐酸盐 Sarecycline hydrochloride | 1035979-44-2 | 1mg | 1800元 |
2024/01/25 | HY-13858A | (4S,4AS,5AR,12AS)-4-(二甲基氨基)-1,4,4A,5,5A,6,11,12A-八氢-3,10,12,12A-四羟基-7-[(甲氧基甲基氨基)甲基]-1,11-二氧代-2-并四苯甲酰胺盐酸盐 Sarecycline hydrochloride | 1035979-44-2 | 5mg | 5200元 |